相关实验视频

Updated: May 30, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

使用患者衍生诱导的多能干细胞预测与代谢功能障碍相关的脂肪性肝病风险

Yuanyuan Qin¹, Parth Chhetri¹, Elizabeth Theusch¹

¹Department of Pediatrics, University of California San Francisco.

bioRxiv : the preprint server for biology

|January 27, 2025

概括

代谢功能障碍相关的性肝病 (MASLD) 可以通过一种新的测试来预测. 来自患者的干细胞显示脂肪积累增加,有助于早期识别MASLD和MASH的风险.

科学领域:

肝病学肝病学是一种肝病学.
干细胞生物学干细胞生物学
遗传学是一个遗传学.

背景情况:

代谢功能障碍相关的性肝病 (MASLD) 是一个日益严重的健康问题,在早期阶段往往是可逆的.
早期识别患有MASLD及其渐进形式MASH的高风险个体对于及时干预至关重要.
以前的研究表明,患有MASLD遗传风险变异的患者衍生诱导多能干细胞 (iPSC) 积累了更多的脂质.

研究的目的:

开发和验证基于iPSC的MASLD风险预测工具.
评估功能性脂质积累试验在iPSC中的有用性,以预测MASLD和MASH的发展.

主要方法:

诱导多能干细胞 (iPSC) 由患者和对照组在三个不同的队列中生成.
油酸诱导的细胞内脂质积累在iPSCs中得到量化.
基于iPSC的MASLD风险评分是使用脂质积累数据开发的,并测试了预测准确性.

主要成果:

与所有队列中的对照组相比,MASLD/MASH病例在iPSC中始终显示了较高的油酸诱导脂质积累.
开发的基于iPSC的风险评分显示了预测能力,在各队列中具有不同的灵敏度和特异性 (例如,在UCSF队列中75%的灵敏度和100%的特异性).
性能的变化可能归因于疾病严重程度和患者心脏代谢概况的差异.

结论:

在受试者衍生的iPSC中,功能性脂质积累是MASH发展的有希望的指标.
基于iPSC的风险评分显示了有可能识别患MASLD风险的个体.
进一步验证更大,多样化的队列和探索额外的细胞表型是必要的,以提高MASLD监测和预防的预测准确性.

关键词:

功能性脂质评估功能性脂质评估在 MASLD 队伍中.预防 MASLD 的策略.一个人的个人敏感性.来自患者的iPSCs.精准医学是一门精准医学.

更多相关视频

Robust Differentiation of Human iPSCs into a Pure Population of Adipocytes to Study Adipocyte-Associated Disorders

Robust Differentiation of Human iPSCs into a Pure Population of Adipocytes to Study Adipocyte-Associated Disorders

Published on: February 9, 2022

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

相关概念视频

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.